PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: marketing

Valcyte Master USPI - Genentech

← Back to document page

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VALCYTE ® safely and effectively. See full prescribing information …

  Information, Prescribing, Prescribing information, Genentech, Valcyte

Download Valcyte Master USPI - Genentech

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Documents from same domain

HIGHLIGHTS OF PRESCRIBING INFORMATION …

www.gene.com

1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TAMIFLU safely and effectively. See full prescribing information for

  Information, Prescribing, Prescribing information, Tamiflu

Initial dose of 4 mg/kg over 90 minute IV infusion, …

www.gene.com

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information …

  Information, Prescribing, Prescribing information

HIGHLIGHTS OF PRESCRIBING INFORMATION The …

www.gene.com

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for

  Information, Prescribing, Prescribing information

Reference ID: 4212951 - Genentech

www.gene.com

1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information …

  Information, Reference, Genentech

HIGHLIGHTS OF PRESCRIBING INFORMATION - Genentech

www.gene.com

2 FULL PRESCRIBING INFORMATION WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Herceptin administration can …

  Information, Prescribing, Prescribing information, Infusion, Genentech

HIGHLIGHTS OF PRESCRIBING INFORMATION The dose for …

www.gene.com

full prescribing information warning: fatal infusion reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive

  Information, Prescribing, Prescribing information, Infusion

OCREVUS Prescribing Information - Genentech

www.gene.com

Hepatitis B Virus Screening Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBVtests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV

  Information, Patients, Virus, Prescribing, Prescribing information, Hepatitis, Genentech, Hepatitis b virus

HIGHLIGHTS OF PRESCRIBING INFORMATION ACTEMRA …

www.gene.com

162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response Patients at or above 100 kg weight 162 mg administered subcutaneously every week Giant Cell Arteritis (2.2) Recommended Adult Subcutaneous Dosage: The recommended dose of ACTEMRA for adult patients with GCA is 162 mg

  Information, Prescribing, Prescribing information, 162 mg

XOLAIR Prescribing Information - Genentech

www.gene.com

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of XOLAIR therapy. (5.4) Eosinophilic Conditions: Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or Fever, Arthralgia, and Rash: Stop XOLAIR if patients develop signs and sickness. (5.6)

  Information, Prescribing, Prescribing information, Corticosteroid, Genentech

XOFLUZA Prescribing Information - Genentech

www.gene.com

Hypersensitivitysuch as anaphylaxis, angioedema,urticaria,and erythema multiforme: Initiate appropriate treatment if an allergic-like reaction occurs or is suspected. (5.1) Risk of bacterial infection:Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as,a complication of influenza.

  Information, Prescribing, Prescribing information, Genentech, Urticaria, Angioedema